Safety and Efficacy of [177Lu]Lu-rhPSMA-10.1 Re-Challenge Therapy in Progressive mCRPC after [177Lu] Lu-PSMA I&T Therapy: Preliminary Results

被引：0
|
作者：
Gaeble, A. [1 ]
Enke, J. [1 ]
Amerein, A. [1 ]
Viering, O. [1 ]
Rinscheid, A. [2 ]
Kircher, M. [1 ]
Wienand, G. [1 ]
Pfob, C. [1 ]
Lapa, C. [1 ]
Dierks, A. [1 ]
Bundschuh, R. [1 ]
机构：
[1] Univ Augsburg, Nucl Med, Fac Med, Augsburg, Germany
[2] Univ Hosp Augsburg, Med Phys & Radiat Protect, Augsburg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0565
引用
收藏
页码：S654 / S655
页数：2
相关论文
共 50 条
  • [21] Clinical dosimetry study of kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T
    Uijen, M.
    Prive, B.
    van Herpen, C.
    Gotthardt, M.
    Konijnenberg, M.
    Peters, S.
    Nagarajah, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S111 - S112
  • [22] Cancer-control outcomes with [177Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients
    Wenzel, Mike
    Siech, Carolin
    Garcia, Cristina Cano
    Humke, Clara
    Groener, Daniel
    Kriegmair, Maximilian
    Graefen, Markus
    Maurer, Tobias
    Salomon, Georg
    Banek, Severine
    Chun, Felix K. H.
    Mandel, Philipp
    THERANOSTICS, 2025, 15 (07): : 2672 - 2679
  • [23] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [24] 177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T
    Bundschuh, Ralph A.
    Pfob, Christian H.
    Wienand, Georgine
    Dierks, Alexander
    Kircher, Malte
    Lapa, Constantin
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) : 337 - 338
  • [25] Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Kostos, Louise Kathleen
    Lai, William Yu Ching
    Lambroglou, Peter
    Medhurst, Elizabeth
    Buteau, James Patrick
    Sandhu, Shahneen
    Tran, Ben
    Spain, Lavinia Anne
    Conduit, Ciara
    Wallace, Roslyn
    Alipour, Ramin
    Akhurst, Timothy J.
    Kong, Grace
    Cardin, Anthony
    Saghebi, Javad
    Kumar, Aravind Ravi
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [26] Radiochemical aspects of synthesis and analysis of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T single-dose preparations
    Larenkov, Anton
    Rakhimov, Marat
    Pavlenko, Ekaterina
    Kodina, Galina
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S152 - S152
  • [27] EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
    Fanti, Stefano
    Kunikowska, Jolanta
    Walz, Jochen
    Witjes, Wim
    Bjartell, Anders
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (10) : 3328 - 3329
  • [28] Comparative preclinical biodistribution, dosimetry and endoradiotherapy in mCRPC of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
    Yusufi, N.
    Nekolla, S.
    Wurzer, A.
    Herz, M.
    D'Alessandria, C.
    Weber, W.
    Wester, H. J.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S642 - S643
  • [29] EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
    Stefano Fanti
    Jolanta Kunikowska
    Jochen Walz
    Wim Witjes
    Anders Bjartell
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3328 - 3329
  • [30] The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Feldmann, Georg
    Brossart, Peter
    Fimmers, Rolf
    Essler, Markus
    Holdenrieder, Stefan
    Ahmadzadehfar, Hojjat
    PROSTATE, 2020, 80 (01): : 17 - 27
12345